A new enzyme-linked immunosorbent assay with Treponema paUlidum antigen bound to ferrous metal beads (Syphilis Bio-EnzaBead; Litton Bionetics Laboratory Products) was compared with the standard fluorescent treponemal antibody-absorption test for syphilis. Bio-EnzaBead and fluorescent treponemal antibody-absorption tests were done on 218 specimens from documented cases of syphilis, on 315 sera from individuals with diseases other than syphilis, and on sera submitted to a public health laboratory for premarital (304 specimens) or diagnostic (501 specimens) tests for syphilis. Agreement between the Bio-EnzaBead and reference tests ranged from 93.0% for sera for the diagnostic test to 99.5% for sera from patients with syphilis. The overall agreement among the 1,338 sera tested was 96.3%. (14). The guidelines describe the specimen categories and serum panels to be examined and the calculations to be made. Specimen categories are (i) documented syphilis, (ii) diagnostic problems, (iii) presumed normals, and (iv) disorders other than syphilis. Serum panels are multiple samples of graded reactivity. The sensitivity, specificity, and agreement for the tests compared and the reproducibility of the test being evaluated were calculated.
The serodiagnosis of syphilis and other treponematoses depends to a large extent on the results of a nontreponemal reagin test, supplemented when indicated by a confirmatory treponemal antibody test (1, 3, 5) . Tests for treponemal antibody currently recognized as standard procedures are the fluorescent treponemal antibody-absorption (FTA-ABS) and FTA-ABS double-staining procedures and the microhemagglutination assay for Treponema pallidum antibodies and hemagglutination treponemal test for syphilis (2, 4, 8, 15) .
A new test, an enzyme-linked immunosorbent assay (ELISA) for treponemal antibody, has now been developed by Litton Bionetics Laboratory Products, Charleston, S.C. The technique, called Syphilis Bio-EnzaBead, has recently been recognized by the Centers for Disease Control as a provisional treponemal test for syphilis (Reagents Evaluation Program Supplement no. 28, 1984) . The test involves the use of Treponema pallidum (Nichols strain) organisms fixed on ferrous metal beads as solid-phase antigen, peroxidase-conjugated anti-human immunoglobulin as the second antibody, and 2,2'-azino-di(3-ethyl-2,3-dihydro-6-benzthiazolinesulfonate) (ABTS) as the enzyme (14) . The guidelines describe the specimen categories and serum panels to be examined and the calculations to be made. Specimen categories are (i) documented syphilis, (ii) diagnostic problems, (iii) presumed normals, and (iv) disorders other than syphilis. Serum panels are multiple samples of graded reactivity. The sensitivity, specificity, and agreement for the tests compared and the reproducibility of the test being evaluated were calculated.
Specimens. Serum specimens from the Centers for Laboratories and Research and the Albany Medical Center Hospital were used. Samples were kept not more than 3 days at 5°C or were stored at -20 or -70°C before the tests. The following groups were tested: (i) sera from documented syphilis cases, comprising 218 VDRL-, ART-, and FTA-ABSreactive sera from untreated primary (3 specimens), secondary (9 specimens), early latent (less than 1 year duration) (7 specimens), and late latent (5 specimens) disease, and from treated primary (62 specimens), secondary (45 specimens), and late latent (87 specimens) disease; (ii) specimens for serodiagnosis of syphilis, comprising 501 VDRL-reactive sera; (iii) presumed-normal sera, comprising 304 VDRL-and ART-nonreactive premarital samples; and (iv) sera from individuals with nontreponemal disorders, comprising 315 VDRL-nonreactive sera unequivocally reactive in serological tests for diseases other than syphilis (see Table 2 ). Group (i) sera had been tested by FTA-ABS and stored at -70°C. Other serum groups were examined by FTA-ABS on the day before, or on the day of, the Bio-EnzaBead tests. Tests were done on various sera from the specimen groups by different technicians who had no knowledge of the results of the other treponemal tests.
Reproducibility panel. A panel of 60 coded specimens derived from six serum pools of graded reactivity were examined. The specimens were tested at a rate of six each day for five consecutive test days, and six on one day during each of the five following test weeks.
RESULTS
The Bio-EnzaBead test was reactive with all but one of the 218 specimens from documented cases of syphilis. The nonreactive specimen was from a patient who had been treated for late latent disease. The indicator color of the first ELISA test of that serum was <1+; a second test, conducted simultaneously with a confirmatory FTA-ABS test, was also seen as <1+. The FTA-ABS test was read as 3+, and the specimen was therefore recorded as Bio-EnzaBead nonreactive, FTA-ABS reactive. No differences were observed in the extent of substrate color intensity among the untreated and treated or early and late disease categories. Negligible (<1+) color was seen in the control wells of three sera, but since the test well colors were judged to be greater than 1+ the sera were recorded as reactive.
The findings with presumed normal specimens are shown in Table 1 . The results agreed for 299 of the 304 sera. The percent agreement was therefore 98.4%. The specificity of the Bio-EnzaBead test was 98% (298/304); that of the FTA-ABS test was 98.4% (299/304).
The Bio-EnzaBead and FTA-ABS test results on specimens submitted for the serodiagnosis of syphilis agreed for 466 of the 501 specimens ( Table 1 ). The 93% agreement is the lowest found for any of the serum groups. Moreover, the number of Bio-EnzaBead and FTA-ABS minimum (1+) reactions and equivocal (<1+) findings that necessitated repeat testing were highest with this serum category.
Results of tests on specimens from diseases other than syphilis are shown in Table 2 . There was agreement between the tests with 307 (97.5%) of the 315 sera.
All of the serological test results are summarized in Table  3 . Overall agreement between the two procedures was 96.5%.
The reproducibility of the Bio-EnzaBead test with the special coded sera is shown in Table 4 . The test readings made during this study were exactly the same as those recorded for the parent serum pools in 37 of 60 trials (63.3%) and within one gradation of that expected in 58 of 60 trials (96.6%).
DISCUSSION
The excellent agreement between the Bio-EnzaBead and FTA-ABS results with specimens from confirmed cases of syphilis indicates that the Bio-EnzaBead test is as effective as the reference test in detecting treponemal antibody. The 99.5% overall sensitivity with sera from cases at all stages of syphilis compares favorably with values of 89.3 and 99.0% reported for conventional ELISAs (12, 16) . Furthermore, the Bio-EnzaBead test was reactive with all 65 primary and 86 of 87 late latent sera. The test therefore detects early as It is difficult to evaluate the findings obtained with the sera submitted for diagnostic tests because the specimens do represent diagnostic problems (5, 11) . It is likely, however, that the smallest amount of antibody present in some sera was at or near the minimum amount detectable by either or both of the tests. A greater proportion of discrepancies therefore occurred (6.9% of the problem sera examined) than would be expected (or were found) with normal sera containing no antibody (1.6% discrepancies) or with sera containing measureable amounts of antibody from individuals with syphilis (0.5%).
The Bio-EnzaBead test was reactive with 14 specimens in the category of diseases other than syphilis (4.4% of the 315 tested). This apparent false-positive finding is comparable to the 10 (3.2%) reactive with the FTA-ABS test. The greatest number of reactive sera, nine Bio-EnzaBead and seven FTA-ABS, were found in the antinuclear antibody (ANA) serum group. The disproportionate number of reactive ANA sera may be due in part to nucleoprotein on the surface of the T. pallidum antigen (7, 9, 10) . No (4, 17) .
The excellent reproducibility of the Bio-EnzaBead technique may be attributed to the use of beads for the solidphase immunochemistry and to the efficiency with which the beads are manipulated (13) . Factors that contribute to the uniformity and precision of the test process include (i) the relatively large and regular surface area of the beads, which provides for greater and more consistent exposure to antigen than is obtainable with conventional antigen-coated tubes or wells; (ài) the simultaneous movement of beads so that reaction, wash, and stop times are identical for all specimens, in contrast to the serial addition of reagents made in more typical assays; and (iii) the abrupt removal of beads and hence enzyme complexes from the final. indicator solution so that there is a more definitive interruption of substrate color development than may be achieved by the addition of an enzyme stop only.
The Bio-EnzaBead test is easy to perform. No special training, microscopy, or other instrument skills are needed. The reagents are stable for 28 days after opening. Any number (up to 90) of specimens may be processed by a technician in one test day.
In conclusion, the findings recommend consideration of the Syphilis Bio-EnzaBead test as an alternative to the FTA-ABS test.
